EMA Launches Review of Clot Risk With AstraZeneca COVID Vaccine

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) is investigating cases of thromboembolic events related to AstraZeneca's COVID-19 vaccine, but says the benefits currently still outweigh risks.

from Google Alert - Business https://ift.tt/2OkU9bY
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) is investigating cases of thromboembolic events related to AstraZeneca's COVID-19 vaccine, but says the benefits currently still outweigh risks. https://ift.tt/eA8V8J

Comments

Popular posts from this blog

Jobless Rate Drops

Electrolytic Fixed Power Capacitors Market Competitive intelligence & regional outlook 2020

USU project among finalists for $3 million solar energy tech prize